睾丸激素溶液2％对低肿瘤男性的射精功能障碍的影响。
摘要来源：
j j sex med。 2016年8月; 13（8）：1220-6。 PMID： 27436077“> 27436077 Darius A Paduch，Craig f donatucci
文章隶属关系：Mario Maggi
摘要：
简介： hypogonadism被定义为男性睾丸激素水平降低。 Hypogonadism can be accompanied by erectile, orgasmic, and ejaculatory dysfunction.
AIMS: To evaluate whether treatment with testosterone solution 2% (testosterone) could improve ejaculatory function in a cohort of hypogonadal男性。
方法： 性活跃，性低下男性至少18岁（总TE）stosterone<300 ng/dL) were randomized to receive testosterone or placebo for 12 weeks.
MAIN OUTCOME MEASURES: Effects of testosterone on primary outcomes were evaluated using the International Index of Erectile Function (IIEF) and the Mens Sexual Health Questionnaire, Ejaculatory Dysfunction, Short Form （MSHQ-EJD-SF）问卷。使用协方差分析来计算处理差异。
结果： 总共715名男性（平均年龄= 55岁）被随机分配到安慰剂（n = 357）或testosterone（n = 358）。报告IIEF分数的大多数性活跃男性具有一定程度的勃起功能障碍（IIFER勃起功能得分<26）。尽管与安慰剂相比，睾丸激素组的射精功能得分（MSHQ-EJD-SF）有所提高（p <.001），但“烦恼”项目的改善没有达到统计学意义。睾丸激素中与治疗相关的不良事件影响至少1％患者的E组是血细胞比容，上呼吸道感染，关节痛，燃烧感，疲劳，前列腺特异性抗原，红斑和咳嗽的增加。 Few patients in either treatment group developed at least one adverse event leading to discontinuation (testosterone = 1.98% vs placebo = 3.09%; P = .475).
CONCLUSION: Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo,如MSHQ-EJD-SF评估。但是，两组之间的“困扰”改善在统计学上并没有差异。睾丸激素治疗通常耐受性良好。